Abstract
Increasing the knowledge about the safety of medical products remains a top priority throughout the pharmaceutical development life cycle and particularly after regulatory approval when the products are used in real-world populations. The increasing availability and use of observational healthcare data, such as administrative claims and electronic health records, provides opportunity for generating better information to support therapeutic decision-making. Analysis of observational databases is quite different from randomized clinical trials, and offers unique opportunities for exploratory visualization to complement traditional epidemiologic investigations. The Observational Medical Outcomes Partnership was established to conduct methodological research on the appropriate use of observational data to identify and evaluate the effects of medical products in the real world. Several visualization tools were developed throughout the process, which demonstrate the value in combining standardized analytics with interactive graphics. These tools include a patient profile to study longitudinal patterns within clinical observations for a given person; a cohort profile to evaluate collections of patients; a treemap to assess disease prevalence across a database; a trellis scatterplot to investigate subgroup differences in drug utilization; a heatmap to support evaluation of high-dimensional confounding adjustment; and a multi-method forest plot to enable sensitivity analyses of estimated effects of drug and outcomes. This chapter illustrates these visualizations through a case study exploring the relationship between ACE inhibitor exposure and the subsequent health event angioedema.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Agbabiaka TB, Savovic J, Ernst E (2008) Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf 31(1):21–37
ALLHAT (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23):2981–2997
Almenoff J, Tonning JM, Gould AL et al (2005) Perspectives on the use of data mining in pharmacovigilance. Drug Saf 28(11):981–1007
Arimone Y, Miremont-Salame G, Haramburu F et al (2007) Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions. Br J Clin Pharmacol 64(4):482–488
Bandekar MS, Anwikar SR, Kshirsagar NA (2010) Quality check of spontaneous adverse drug reaction reporting forms of different countries. Pharmacoepidemiol Drug Saf 19(11):1181–1185
Bennett CL, Nebeker JR, Yarnold PR et al (2007) Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med 167(10):1041–1049
Berlin JA, Glasser SC, Ellenberg SS (2008) Adverse event detection in drug development: recommendations and obligations beyond phase 3. Am J Public Health 98(8):1366–1371
Brown NJ, Ray WA, Snowden M, Griffin MR (1996) Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 60(1):8–13
Chalmers D, Whitehead A, Lawson DH (1992) Postmarketing surveillance of captopril for hypertension. Br J Clin Pharmacol 34(3):215–223
Chobanian A (2009) The joint national committee on prevention detection and evaluation of high blood pressure. US Department of Health and Human Services NHLBI, Bethesda, MD
Chou R, Helfand M, Carson S (1995) Drug class review on angiotensin converting enzyme inhibitors. Final report. Portland, OR: Oregon Health & Science University
DuMouchel W (1999) Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Statist 53(3):177–189
Foody JM, Mendys PM, Liu LZ, Simpson RJ Jr (2010) The utility of observational studies in clinical decision making: lessons learned from statin trials. Postgrad Med 122(3):222–229
Hennessy S (2006) Use of health care databases in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 98(3):311–313
Hennessy S, Leonard CE, Palumbo CM, Newcomb C, Bilker WB (2007) Quality of Medicaid and Medicare data obtained through Centers for Medicare and Medicaid Services (CMS). Med Care 45(12):1216–1220
Hill AB (1965) The environment and disease: association or causation? Proc R Soc Med 58:295–300
Knapp P, Raynor DK, Berry DC (2004) Comparison of two methods of presenting risk information to patients about the side effects of medicines. Qual Saf Health Care 13(3):176–180
Kostis JB, Shelton B, Gosselin G et al (1996) Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am Heart J 131(2):350–355
Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279(15):1200–1205
Lewis JD, Brensinger C (2004) Agreement between GPRD smoking data: a survey of general practitioners and a population-based survey. Pharmacoepidemiol Drug Saf 13(7):437–441
Madigan D, Ryan P (2011) What can we really learn from observational studies?: the need for empirical assessment of methodology for active drug safety surveillance and comparative effectiveness research. Epidemiology 22(5):629–631
Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE (2008) Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 51(6):1624–1630
Norén G, Bate A, Hopstadius J, Star K, Edwards I (2008) Temporal pattern discovery for trends and transient effects: its application to patient records. Paper presented at: Proceeding of the 14th ACM SIGKDD international conference on knowledge discovery and data mining, Las Vegas, Nevada, USA
Norris S, Weinstein J, Peterson K, Thakurta S (2010) Drug class review: direct renin inhibitors, angiotensin converting enzyme inhibitors, and angiotensin II receptor blockers. Accessed on Oct 8, 2012, http://derp.ohsu.edu/about/fi nal-document-display.cfm Accessed Oct 8, 2012.
Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE (2011) Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc 19(1):54–60
Public Law 110–85 (2007) Food and Drug Administration Amendments Act of 2007
Papay JI, Clines D, Rafi R et al (2009) Drug-induced liver injury following positive drug rechallenge. Regul Toxicol Pharmacol 54(1):84–90
Perrio M, Voss S, Shakir SA (2007) Application of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance. Drug Saf 30(4):333–346
Polinski JM, Schneeweiss S, Levin R, Shrank WH (2009) Completeness of retail pharmacy claims data: implications for pharmacoepidemiologic studies and pharmacy practice in elderly patients. Clin Ther 31(9):2048–2059
Racoosin J (2009) FDA’s sentinel initiative—a national strategy for monitoring medical product safety. 2nd Drug Information Association (DIA) Conference on Signal Detection and Data Mining. New York, NY
Rockhill B, Newman B, Weinberg C (1998) Use and misuse of population attributable fractions. Am J Public Health 88(1):15–19
Rodriguez EM, Staffa JA, Graham DJ (2001) The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf 10(5):407–410
Rosenbaum P (2002) Observational studies. Springer, New York
Schneeweiss S (2009) On guidelines for comparative effectiveness research using nonrandomized studies in secondary data sources. Value Health 10 Sep 2009
Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA (2009) High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 20(4):512–522
Schneeweiss S, Avorn J (2005) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58(4):323–337
Schneeweiss S, Sturmer T, Maclure M (1997) Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf 6(Suppl 3):S51–S59
Speirs C, Wagniart F, Poggi L (1998) Perindopril postmarketing surveillance: a 12 month study in 47,351 hypertensive patients. Br J Clin Pharmacol 46(1):63–70
Stang PE, Ryan PB, Racoosin JA et al (2010) Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med 153(9):600–606
Strom B (2005) Pharmacoepidemiology, 4th edn. Wiley, Chichester
Suissa S, Garbe E (2007) Primer: administrative health databases in observational studies of drug effects—advantages and disadvantages. Nat Clin Pract Rheumatol 3(12):725–732
Szarfman A, Machado SG, O’Neill RT (2002) Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports database. Drug Saf 25(6):381–392
US Department of Health and Human Services, Food and Drug Administration (1999) Managing the risks from medical product use: creating a risk management framework US Department of Health and Human Services, Food and Drug Administration, May 1999
Waller PC, Evans SJ (2003) A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 12(1):17–29
Weatherby LB, Nordstrom BL, Fife D, Walker AM (2002) The impact of wording in “Dear doctor” letters and in black box labels. Clin Pharmacol Ther 72(6):735–742
Whitaker HJ, Farrington CP, Spiessens B, Musonda P (2006) Tutorial in biostatistics: the self-controlled case series method. Stat Med 25(10):1768–1797
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342(3):145–153
Zorych I, Madigan D, Ryan P, Bate A (2011) Disproportionality methods for pharmacovigilance in longitudinal observational databases. Stat Methods Med Res (in print)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, New York
About this chapter
Cite this chapter
Ryan, P. (2012). Using Exploratory Visualization in the Analysis of Medical Product Safety in Observational Healthcare Data. In: Krause, A., O'Connell, M. (eds) A Picture is Worth a Thousand Tables. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-5329-1_21
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5329-1_21
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-5328-4
Online ISBN: 978-1-4614-5329-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)